Malignant peritoneal mesothelioma

Spread of cancer cells of the peritoneal surface was previously associated with the impossibility of curative therapy and short-term survival. Scientific and pharmacological studies have shown that prevention and effective treatment are now a reality. Diffuse malignant peritoneal mesothelioma is the rarest and dangerous abdominal malignancy. The author points to modest results in the systemic treatment contrasts with the modern multimodal approach, which extended the survival of patients. The treatment consists of cytoreductive surgery (CRS) including peritonectomy (PE) and the perioperative application of the combination of cytotoxic agents in hyperthermia (HIPEC). Currently there are studies that show an acceptable mortality, morbidity and profits, including long-term survival in a group of patients with ineffective or exhausted conventional oncological treatment. (author)